A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer

BEV-III/2022 is a double-blind randomized multicenter clinical trial comparing efficacy of bevacizumab (manufactured by Mabscale, LLC) and paclitaxel plus carboplatin to Avastin® and paclitaxel plus carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC. The purpose of the study is to demonstrate equivalence of efficacy and safety of bevacizumab (manufactured by Mabscale, LLC) to Avastin®. Study includes pharmacokinetics assessment.

Trial Details

NCT ID
NCT05654454
Phase
PHASE3
Sponsor
Mabscale, LLC
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Bevacizumab
  • Paclitaxel
  • Carboplatin
Locations (sample)
  • Arkhangelsk, Russia|64.5461,40.55183
  • Ivanovo, Russia|56.99988,40.97257
  • Kaluga, Russia|54.53063,36.27
  • Kazan', Russia|55.78874,49.12214
  • Moscow, Russia|55.75204,37.61781

Key Eligibility Criteria

  • Written informed consent
  • Male and female patients at least 18 years of age
  • Newly diagnosed Stage IIIB/C or IV non-small cell lung cancer (according to Revised Cancer Staging by American Joint Committee on Cancer (AJCC) and…
  • Histologically or cytologically confirmed diagnosis of predominately non-squamous NSCLC

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →